Stay informed about the latest developments in RAS pathway research, regulatory achievements, and company milestones.
Shanghai Daraxon Bio-Pharmaceutical Co., Ltd. announces receipt of FDA Drug Master File (DMF) certificate for Daraxonrasib (RMC-6236), becoming the world's first enterprise to achieve this regulatory milestone.
Recent Phase II clinical trial results demonstrate significant tumor response rates in patients with KRAS G12D and G12V mutant solid tumors treated with Daraxonrasib combination therapy.
Company invests in new GMP-compliant manufacturing facility to scale up production of high-purity RAS inhibitor APIs, ensuring reliable supply for pharmaceutical partners worldwide.
Contact us to learn more about our RAS inhibitor APIs and how we can support your drug development programs.
Contact Us